drug
(drospirenone + ethinylestradiol + levomefolate calcium) + levomefolate calcium
Marketedupdated 3mo agoby Allergan Sales LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 8, 2030
~3.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Jul 17, 2030formulationUS 116177514.0y
- Feb 8, 2030formulationUS 86175973.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 56m ago
Found something off?
comments(0)
5-min edit window · permanent after that